The drug maker relies on the cancer drug Revlimid for more than half of its revenue, but trials of a pancreatic cancer treatment, Abraxane, have also been positive.
Above excerpt from IBD's Investors.com.
Market Direction Model
 |
| Market in Confirmed Uptrend |
This blog post does not constitute an offer of investment advice. This blog is only provided for educational purposes. Please read the Important Blog Disclosure posted in the right channel bar.
No comments:
Post a Comment